12th July 2019
EIT Health Innovation Project
EIT Health Innovation Project Neuro-Wear announced the production of its new series of wearable neural stimulators. Called AxonScan, the device is a highly versatile multi-purpose neural stimulation and recording device.
Neuro-Wear has been seeking to develop a wearable neurotransmitter that uses transcranial current stimulation (TCS) to help patients suffering from neurological or psychiatric diseases, such as movement disorders, tinnitus, chronic pain or depression. The innovation can make it easier for these patients to get around by themselves, and to take care of themselves. TCS technology involves delivering low-current electricity to a patient’s scalp. It is a noninvasive means of altering nerve activity through outside stimulation.
AxonScan’s current production has five independent stimulation channels, each one capable of delivering direct current stimulation, sine wave stimulation, pulsatile stimulation or any other stimulation waveform. This wide range of waveforms means the AxonScan can be used for many applications, such as transcranial direct current stimulation (tDCS), transcranial alternating current stimulation (tACS), peripheral nerve stimulation, operating room testing, etc. AxonScan’s recording capabilities are planned for activation in the next production series.
Helping to close the loop
One of the aims of the Neuro-Wear project is to develop a closed-loop neural stimulator. The current production of AxonScan takes input from a sensor, such as an accelerometer, and uses it to modulate the stimulation waveform. This will enable the device to be used for the delivery of closed-loop neural stimulation therapy to patients with movement disorder.
The next steps in the Neuro-Wear project are to complete electrical safety testing of the AxonScan device and to begin patient testing on patients with movement disorder.
Visit the Neuro-Wear Innovation Project webpage for more information.
Corify Care raises €6M to revolutionise cardiac care
A significant milestone for the company.
Luminate Medical secures additional $2.5M to advance cancer care
A significant milestone for the company.
Longenesis teams up with Novartis for digital heart care innovation
Pilot project for treatment of cardiovascular diseases.